Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients

Richard H Lash, Robert M Genta, Christopher M Schuler

ABSTRACT

Background and aims  Sessile serrated adenomas (SSAs) are recognised as precursors to microsatellite unstable adenocarcinomas. This study attempts to estimate the progression rate of SSAs based upon the epidemiology of a large cohort as well as identify relationships to other colorectal polyps.

Methods  Pathological reports generated at Caris Diagnostics from 290 810 colonoscopic specimens on 179 111 patients were analysed using computerised algorithms.

Results  SSAs with or without dysplasia/carcinoma (SSA +/-) were identified in 2416 specimens from 2139 patients (54% women). The distribution of SSA +/- was: right-sided (81.2%); left-sided (11.2%); both right- and left-sided (3.2%); not specified (4.3%). There were 1816 (85%) patients without dysplasia (SSA-), 257 (12%) with low-grade dysplasia (SSA-LD), 45 (2%) with high-grade dysplasia (SSA-HD) and 21 (1%) with adenocarcinoma (SSA-CA). The difference in median age between almost all groups was significant (SSA- = 61 years versus SSA-LD = 66 years (p < 0.001) vs SSA-HD = 72 years (p = 0.002) vs SSA-CA = 76 years (p = 0.07, NS)). Women comprised 53% of the SSA- group (968/1816), 57% of the SSA-LD group (147/257), 69% of the SSA-HD group (31/45) and 76% of the SSA-CA group (16/21), being more likely to have high-grade dysplasia (OR 1.94, 95% CI 1.03 to 3.67) and adenocarcinoma (OR 2.80, 95% CI 1.02 to 7.68).

Conclusions  1.7% of patients with mucosal polyps had SSAs (with and without dysplasia), more commonly in women and primarily in the right colon. Dysplasia or carcinoma was identified in 15% of patients and significantly disproportionally among women. Based on significant age differences between groups, there appears to be a stepwise progression of dysplasia and carcinoma in SSAs over 10 to 15 years, a period two to three times longer than that for conventional adenomas.

METHODS

Study setting  This study was approved by the Caris Diagnostics Institutional Review Board. Colorectal biopsies from Caris Diagnostics, a subspecialty gastrointestinal pathology laboratory receiving specimens from gastroenterologists operating in outpatient endoscopy centres in 56 states, the District of Columbia and Puerto Rico, were routinely fixed in 10% buffered formalin and embedded in paraffin prior to sectioning. Slides were prepared with 4 μm thick sections and stained with H&E. Interpretations were performed by an experienced group of gastrointestinal pathologists who share a common approach to biopsy evaluation and daily conferencing to review criteria and interpretation of problematic cases.

Histopathological criteria  Among serrated polyps, SSAs were recognised by their architectural and (secondarily) cytological features. These lesions were, by definition, sessile, with lateral serration of the glandular epithelium and branching and horizontal growth of crypt bases (figure 1). Other histological features supporting the diagnosis of SSA were maintenance of basal goblet cells and the presence of mitotic figures in the middle and upper third of the crypts. When there was low-grade dysplasia (figure 2), characterised by nuclear hyperchromasia and elongation, pseudostatification, apoptosis, increased mitotic activity, and loss of mucin as is seen in conventional adenomas, the polyp was classified as SSA with low-grade dysplasia (SSA-LD). When there was high-grade dysplasia (figures 3, 4), characterised by greater nuclear enlargement, with nucleoli, loss of polarity and accompanying architectural complexity (eg, cribiforming), the polyp...
was classified as SSA with high-grade dysplasia (SSA-HD). Rarely, the dysplasia resembled that of a traditional serrated adenoma, including more uniformly enlarged nuclei, eosinophilic cytoplasm and the architectural presence of so-called ectopic crypt formation. Invasive adenocarcinomas arising within identifiable SSAs (typically also containing low- and high-grade dysplasia) were designated SSA-CA.

Hyperplastic polyps (HP) were defined as polyps with predominantly superficial serrations, narrow basilar crypt regions, proliferative zones limited to the lower portions of the crypts and no cytological dysplasia. For the purpose of this analysis, polyps with some characteristics considered suggestive but not diagnostic of SSA (typically rare dilated or distorted crypts in a somewhat sessile polyp) were amalgamated with the hyperplasic polyps. The term ‘traditional serrated adenoma’ (TSA) was used to describe serrated polyps with columnar configuration of the glandular epithelium, eosinophilic cytoplasm and uniform, non-stratified glandular dysplasia.

Adenomatous polyps were recognised by conventional-type surface epithelial proliferation and dysplasia in which the columnar cells lining the polyps had hyperchromatic, pseudostratified, pencillate nuclei. These polyps were subclassified based upon architectural features (villous and tubulovillous) and the presence or absence of high-grade dysplasia. The resulting groups, based upon the most advanced lesion, included tubular adenomas without high-grade dysplasia (TA), tubular adenomas with high-grade dysplasia, tubulovillous or villous adenomas without high-grade dysplasia, and tubulovillous/villous adenomas with high-grade dysplasia. Polyps with distinctly separate areas of conventional adenoma and hyperplastic polyp were classified as ‘mixed hyperplastic adenomatous polyps’ and were distinguished from SSA-LD. Adenocarcinoma with no evidence of adjacent SSA was designated ADENOCA.
Data acquisition
Diagnostic reports on 290,810 colonoscopic specimens from 179,111 patients generated between 1 April 2007 and 31 March 2008 were stored in a Microsoft Access Database and analysed using algorithms programmed in Visual Basic for Applications. Characterisation of data was validated through searches using structured query language. The presence or absence of each type of polyp was recorded for each specimen. When analysing patient-specific data, polyps from multiple endoscopic procedures were considered in aggregate, and the patient’s age was averaged among all encounters over the 1-year study period. Statistical calculations for uncorrected $\chi^2$, Fisher exact, Student t and Mann-Whitney Rank Sum tests (for non-parametric data) were performed using SigmaStat v3.5 (Systat Software, Richmond, California); proportions t tests and ORs were used as appropriate.

RESULTS
The median age of all patients with colonoscopic biopsies was 59 years (average age 59.4 years). There were 88,889 women (49.6%), 90,219 men (50.4%) and three unspecified. Only 1757 patients (1%) had biopsies from more than one endoscopy (1650 with two encounters, 77 with three encounters and 10 with four to six encounters). Mucosal polyps were present in 185,469 specimens from 128,106 patients. A summary of the different types of polyps found in all patients is depicted in figure 5.

SSAs
We identified 2416 specimens from 2139 patients with at least one SSA (with or without dysplasia/carcinoma). This SSA+/- group consisted of 1162 (54.3%) women and 977 (45.7%) men. The distribution of SSA+/- in patients was: right-side=1757 patients (81.2%); left-side=240 patients (11.2%); both right and left-side=70 patients (3.2%); not specified=92 patients (4.3%). When stratifying patients with SSAs based upon the most advanced polyp (highest grade dysplasia/carcinoma) present, there were 1816 patients without dysplasia (SSA-), 257 patients with low-grade dysplasia (SSA-LD), 45 patients with high-grade dysplasia (SSA-HD) and 21 patients with adenocarcinoma arising within an SSA (SSA-CA). Patients with SSA+/- had a median age of 62 years with a range of 23 to 95 years. The median age of patients with SSA- was 61 years, SSA-LD was 66 years, SSA-HD was 72 years, and SSA-CA was 76 years. The difference in median age between patients with SSAs without dysplasia (SSA-) and those with dysplasia or carcinoma (SSA-LD/SSA-HD/SSA-CA) was significant ($p<0.001$); in fact, there were significant differences between the median age of most subgroups (SSA- vs SSA-LD ($p<0.001$), SSA-LD vs SSA-HD ($p=0.002$), SSA-HD vs SSA-CA ($p=0.07$, NS)). There were no significant differences between the median ages of men and women within each subgroup (SSA- ($p=0.983$), SSA-LD ($p=0.378$), SSA-HD ($p=0.868$, $z=0.050$: 0.050) and SSA-CA ($p=0.526$, $z=0.050$: 0.050)).

SSA+/- were more common in women than in men (OR=1.21, 95% CI 1.11 to 1.32), and women comprised 53% of the SSA- group (968/1816), 57% of the SSA-LD group (147/240), 69% of the SSA-HD group (31/45) and 76% of the SSA-CA group (16/21). The predominance of women in each group was significant ($p<0.001$ to $p=0.002$), and, compared with our population undergoing colonoscopy, women were over-represented among patients with SSA- (OR 1.16, 95% CI 1.06 to 1.27), SSA-LD (OR 1.36, 95% CI 1.06 to 1.74), SSA-HD (OR 2.25, 95% CI 1.20 to 4.23) and SSA-CA (OR 3.25, 95% CI 1.19 to 8.87). Even among patients with SSAs, already predominantly women, women appeared to be at higher risk of developing high-grade dysplasia (OR 1.94, 95% CI 1.0251 to 3.6708) and adenocarcinoma (OR 2.80, 95% CI 1.02 to 7.68) (figure 6).

Non-serrated adenomas and adenocarcinomas
There were 117,165 specimens from 86,141 patients with at least one conventional adenoma with or without high-grade dysplasia/carcinoma (AD+/-). These patients had a median age of 62 years. The AD+/- group consisted of 36,601 women (42.3%) and 49,540 men (57.7%). The total number of patients, proportion of men and women, and median ages of the patients in these groups are summarised in table 1. There were significantly fewer women in the AD+/- group than men (OR=0.58, 95% CI 0.57 to 0.59).

The difference in median age between patients with SSA- and those with SSA-CA was 15 years. In contrast, there was only a 5-year difference between the median age of patients with TA and those with ADENOCA (figure 7).

Serrated polyps other than SSAs
There were 77,891 specimens from 64,094 patients with at least one hyperplastic polyp (HP). Their median age was 59 years (9–104). HPs were less common in women (50,458; 47.5%) than in men (34,636; 52.5%).

TSAs with or without high-grade dysplasia were seen in 722 specimens from 709 patients. Of the 698 patients having TSAs without high-grade dysplasia, there were 355 (50.9%) women and 343 (49.1%) men with a median age of 63 years. Only 11 patients with a median age of 65 years had a TSA with high-grade dysplasia. There was no significant difference in the

Figure 5 Total number of patients with each type of polyp. The median age and percentage of women are indicated in each major box. ADENOCA, adenocarcinoma without evidence of precursor sessile serrated adenoma; HP, hyperplastic polyp; MHAP, mixed hyperplastic-adenomatous polyp; MHAPHD, mixed hyperplastic-adenomatous polyp with high-grade dysplasia; SSA-, sessile serrated adenoma without dysplasia; SSA-CA, adenocarcinoma arising in a sessile serrated adenoma; SSA-HD, sessile serrated adenoma with high-grade dysplasia; SSA-LD, sessile serrated adenoma with low-grade dysplasia; TA, tubular adenoma; TA-HD, tubular adenoma with high-grade dysplasia; TSA, traditional serrated adenoma; TSA-HD, traditional serrated adenoma with high-grade dysplasia; TSA/VA, tubulovillous and villous adenomas; TSA-HD/VA-HD, tubulovillous and villous adenomas with high-grade dysplasia.
proportion of women versus men with TSA without (OR 1.07, 95% CI 0.92 to 1.23) or with high-grade dysplasia (OR 1.83, 95% CI 0.58 to 4.93).

MHAPs with or without high-grade dysplasia (MHAP+/-) were identified in 248 specimens from 245 patients. These polyps were found less frequently in women than men, although the difference was not significant (108 women (44.1%) and 137 men (55.9%); OR 0.80, 95% CI 0.62 to 1.03; p=0.094).

Patients with MHAP without high-grade dysplasia had a median age of 63.5 years while those with high-grade dysplasia had a median age of 69 years.

**DISCUSSION**

**Background, prevalence and distribution of SSAs**

This study provides unique insight regarding the epidemiology and associations of sessile serrated adenomas in a large and geographically broad-based USA patient population undergoing colonoscopy during a 12-month period. All specimens were analysed were examined in a single laboratory where a group of pathologists dedicated to gastrointestinal pathology strives to adhere to rigorous diagnostic criteria. In order to minimise interobserver variation and increase accuracy, we use internally standardised specimen handling, diagnostic criteria and terminology. Consensus is maintained and updated through daily multiheaded microscope conferences, didactic and journal review conferences, a terminology and criteria review committee, and ongoing quality assurance activities. The joint training of pathologists and the adherence to pre-established criteria have been shown to minimise interobserver variability in the diagnosis of specific entities, despite the lack of agreement among independent pathologists, such as epithelial dysplasia in Barrett oesophagus, gastric atrophy and melanocytic dysplasia.

Although we do not claim the complete absence of interobserver variability in this study, a major effort was made in our laboratory to achieve uniformity in the diagnosis of SSA, a relatively novel and still incompletely defined type of polyp. It is arguable that this commitment to achieve uniformity results in a set of interpretations as valid as any single observer’s interpretation of the same group of polyps. As part of this effort, many SSAs without dysplasia and virtually all SSAs with dysplasia or carcinoma evaluated in the year before and during the study period were reviewed at our daily consensus conference.

Our understanding of serrated polyps has evolved since the description of serrated adenomas by Longacre and Fenoglio-Preiser in 1990 and the recognition of sessile serrated adenomas by Torlakovic and Snover in 1996. Since then, it has become clear that the predominantly left-sided ‘traditional’ serrated adenomas (similar to typical adenomas but with a serrated architecture and a unique cytological configuration) are relatively rare compared with the previously underappreciated sessile serrated adenomas, that resemble large hyperplastic polyps. In our study, SSAs were identified in 1.7% patients (similar to the 1.9% prevalence reported by Higuchi et al). SSAs comprised 3.4% of all serrated polyps, less than the 8.3% reported by Higuchi (and up to 22.6% reported in other studies). The lower proportions in this study likely reflect our conservative criteria for inclusion as SSA, since we did not include 3522 patients with 3567 serrated polyps that failed to meet all

**Table 1** Demographic information of patients with selected colorectal polyps

<table>
<thead>
<tr>
<th>Group</th>
<th>Median age (range)</th>
<th>Women (%)</th>
<th>Men (%)</th>
<th>No of patients</th>
<th>No of specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSA</td>
<td>61 (23 to 90)</td>
<td>968 (55.3)</td>
<td>848 (44.7)</td>
<td>1816</td>
<td>2077</td>
</tr>
<tr>
<td>SSA-LD</td>
<td>65 (31 to 95)</td>
<td>147 (57.2)</td>
<td>110 (42.8)</td>
<td>267</td>
<td>271</td>
</tr>
<tr>
<td>SSA-HD</td>
<td>72 (50 to 87)</td>
<td>31 (68.9)</td>
<td>14 (31.1)</td>
<td>45</td>
<td>47</td>
</tr>
<tr>
<td>SSA-CA</td>
<td>76 (61 to 89)</td>
<td>16 (76.2)</td>
<td>5 (23.8)</td>
<td>21</td>
<td>21</td>
</tr>
<tr>
<td>HP</td>
<td>59 (9 to 104)</td>
<td>30458 (47.5)</td>
<td>33636 (52.5)</td>
<td>64094</td>
<td>77891</td>
</tr>
<tr>
<td>HS</td>
<td>63 (23 to 92)</td>
<td>355 (50.9)</td>
<td>343 (49.1)</td>
<td>698</td>
<td>711</td>
</tr>
<tr>
<td>TS</td>
<td>65 (53 to 78)</td>
<td>8 (72.7)</td>
<td>3 (27.3)</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>TA</td>
<td>62 (8 to 106)</td>
<td>31841 (42.2)</td>
<td>43648 (57.8)</td>
<td>75488</td>
<td>105308</td>
</tr>
<tr>
<td>TAV/HAVD</td>
<td>64 (17 to 99)</td>
<td>2991 (45.2)</td>
<td>3625 (54.8)</td>
<td>6616</td>
<td>7554</td>
</tr>
<tr>
<td>TAHD</td>
<td>66 (37 to 92)</td>
<td>351 (41.0)</td>
<td>506 (59.0)</td>
<td>857</td>
<td>969</td>
</tr>
<tr>
<td>ADENOCA</td>
<td>67 (24 to 99)</td>
<td>940 (44.3)</td>
<td>1181 (55.7)</td>
<td>2121</td>
<td>2190</td>
</tr>
<tr>
<td>MHAP</td>
<td>69 (51 to 80)</td>
<td>106 (44.5)</td>
<td>132 (55.5)</td>
<td>238</td>
<td>241</td>
</tr>
<tr>
<td>MHAPHD</td>
<td>69 (51 to 80)</td>
<td>1 (16.7)</td>
<td>5 (88.3)</td>
<td>6</td>
<td>7</td>
</tr>
</tbody>
</table>

ADENOCA, adenocarcinoma without evidence of precursor sessile serrated adenoma; HP, hyperplastic poly; MHAP, mixed hyperplastic-adenomatous poly; MHAPHD, mixed hyperplastic-adenomatous poly with high-grade dysplasia; SSA, sessile serrated adenoma without dysplasia; SSA-CA, adenocarcinoma arising in a sessile serrated adenoma; SSA-HD, sessile serrated adenoma with high-grade dysplasia; SSA-LD, sessile serrated adenoma with low-grade dysplasia; TA, tubular adenoma; TA-HD, tubular adenoma with high-grade dysplasia; TSA, traditional serrated adenoma; TSA-HD, traditional serrated adenoma with high-grade dysplasia; TAV/HAVD, tubulovillous and villous adenomas; TAV/HAVD/VA-HD, tubulovillous and villous adenomas with high-grade dysplasia.
Dysplasia and carcinoma arising in SSAs

We identified low-grade dysplasia in 12.0% of our patients with SSAs, high-grade dysplasia in 2.1% and adenocarcinoma in 1.0%. Remarkably similar proportions of our patients with conventional adenomatous polyps had high-grade dysplasia (2.2%) and adenocarcinoma (2.5%). The percentage of women increased progressively from 53% for SSAs without dysplasia to 57% for SSA with low-grade dysplasia, 69% for SSA with high-grade dysplasia and 76% for SSA with adenocarcinoma. In contrast, no significant gender differences were present in the progression of adenomas to high-grade dysplasia and carcinoma (figure 2).

Over the last several years, it has been suggested that SSAs may progress to adenocarcinoma more rapidly than conventional adenomas.2 3 4 These concerns have led to the suggestion that screening guidelines based upon the progression rates of conventional adenomas may not be adequate for SSAs,17 and surgery for adenocarcinoma arising within SSAs comes from a study of 91 patients with MSI-H adenocarcinomas, in which the mean and median intervals between removal of a ‘hyperplastic-like’ polyp and subsequent mismatch repair-deficient adenocarcinoma were 7.5 and 6.5 years, respectively.1 In a subsequent study of six SSA with carcinoma by the same author, the mean patient age was 69.3 years (range 57.1–83.9 years).2 It is arguable that the evidence presented in this and other studies, suggesting a more indolent course for these lesions, especially without dysplasia, supports the notion that they are best referred to as ‘sessile serrated polyps’. It is also conceivable, however, that while the majority of SSAs follow a stepwise progression to adenocarcinoma over many years, a subset of SSAs may gain specific molecular alterations that cause a more rapid progression to adenocarcinoma. Indeed, Oono et al15 recently reported endoscopic progression of a SSA to early invasive carcinoma within a period of 3 months. For this reason, some authors will likely prefer the term ‘Sessile serrated adenoma’.

While it would be premature to suggest that no aggressive treatment is needed for well-sampled, non-dysplastic and low-grade dysplastic SSAs based on these findings, we would hope that these data provide a stimulus for the development of controlled follow-up studies.

Acknowledgements The authors wish to thank S Gupta, Division of Gastroenterology, UTSW Medical Center at Dallas, for helpful insights and suggestions.

Competing interests None.

Ethics approval Ethics approval was provided by the Caris Diagnostics Institutional Review Board.

Contributors RHL designed the study, interpreted the data, cowrote the manuscript and prepared two figures. RMG designed the study, analysed the data, interpreted the data, cowrote the manuscript and prepared one figure. CMS designed the study, cowrote the manuscript and prepared figures.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


17. Freeman HJ. Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance. World J Gastroenterol 2008;14:3461—3.